Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Statins

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    207 result(s) found for: Statins. Displaying page 9 of 11.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next»
    EudraCT Number: 2009-009888-60 Sponsor Protocol Number: CLCQ908A2203 Start Date*: 2009-07-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the efficacy on blood glucose control and safety of five doses of LCQ908 (2, 5...
    Medical condition: Type II Diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012601 Diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed) FR (Completed) BE (Completed) PL (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2011-004287-30 Sponsor Protocol Number: LAL-CL06 Start Date*: 2014-06-19
    Sponsor Name:Alexion Pharmaceuticals inc
    Full Title: A Multicenter, Open-Label Study of Sebelipase Alfa in Patients with Lysosomal Acid Lipase Deficiency
    Medical condition: Lysosomal Acid Lipase Deficiency (LALD)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004850 10024579 Lysosomal storage disorders HLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed) ES (Completed) GB (Completed) IT (Prematurely Ended) DE (Completed) BE (Completed) HR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-004735-12 Sponsor Protocol Number: 20130286 Start Date*: 2017-04-06
    Sponsor Name:Amgen Inc
    Full Title: A Double Blind, Randomized, Placebo Controlled, Multicenter Study toEvaluate Safety, Tolerability, and Efficacy on LDL-C of Evolocumab (AMG 145) in Subjects with HIV and with Hyperlipidemia and/or ...
    Medical condition: HIV and hyperlipidemia or mixed dyslipidemia.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020604 Hypercholesterolemia LLT
    20.1 100000004861 10020667 Hyperlipidemia LLT
    20.0 100000004848 10020180 HIV positive LLT
    20.0 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PT (Completed) GB (Completed) BE (Completed) ES (Completed) GR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000688-57 Sponsor Protocol Number: AROAPOC3-2002 Start Date*: 2021-11-10
    Sponsor Name:Arrowhead Pharmaceuticals, Inc.
    Full Title: A Double-blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Mixed Dyslipidemia
    Medical condition: Mixed Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10027763 Mixed hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-002967-23 Sponsor Protocol Number: M-17923-30 Start Date*: 2022-01-27
    Sponsor Name:Almirall, S.A.
    Full Title: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adult and Adolescent Patients ...
    Medical condition: atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Completed) PL (Completed) BE (Completed) IT (Completed) NL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000728-41 Sponsor Protocol Number: 06/02-29 jan'07 Start Date*: 2008-09-12
    Sponsor Name:Maastro clinic
    Full Title: A phase I/II trial testing nelfinavir, an inhibitor of Akt signaling, in combination with preoperative chemoradiotherapy in patients with locally advanced rectal cancer
    Medical condition: A phase I/II trial testing nelfinavir, an inhibitor of Akt signaling, in combination with preoperative chemoradiotherapy with locally advanced rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038050 Rectal cancer stage III PT
    9.1 10038051 Rectal cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-000385-38 Sponsor Protocol Number: BEL116472 Start Date*: 2012-05-18
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: BEL116472. A 2 year mechanistic study of belimumab in Idiopathic Membranous Glomerulonephropathy
    Medical condition: Idiopathic Membranous Glomerulonephropathy (IMGN)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-003808-20 Sponsor Protocol Number: EV077/C005 Start Date*: 2011-10-20
    Sponsor Name:Evolva SA
    Full Title: A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EV-077-3201-2TBS in Healthy Subjects and Type 2 Diabetic Subjects
    Medical condition: Healthy subjects and subjects with Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-000824-20 Sponsor Protocol Number: 239/2007 Start Date*: 2008-06-15
    Sponsor Name:UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II
    Full Title: Effects of ezetimibe in association with statins on postprandial lipemia in type 2 diabetic patients
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027433 SOC
    9.1 10013317 HLGT
    9.1 10062060 PT
    9.1 10020661 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001446-25 Sponsor Protocol Number: FHGT002 Start Date*: 2017-09-20
    Sponsor Name:University of Pennsylvania
    Full Title: AAV8-mediated Low Density Lipoprotein Receptor (LDLR) Gene Replacement in Subjects with Homozygous Familial Hypercholesterolemia (HoFH)
    Medical condition: Adults with homozygous familial hypercholesterolemia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-002550-56 Sponsor Protocol Number: D6160C00003 Start Date*: 2005-03-04
    Sponsor Name:AstraZeneca AB
    Full Title: A 24-week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Metformin or Metformin Combined with Fenofibrate) Study to Evaluate the Lipid Metabolic Effects, Glycaemic Effec...
    Medical condition: Men or women diagnosed with type 2 diabetes and treated with diet alone or on treatment with a single oral anti diabetic agent or low doses of two agents, and with diabetic dyslipidaemia; ie low HD...
    Disease: Version SOC Term Classification Code Term Level
    7 10045242 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FI (Completed) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-000706-37 Sponsor Protocol Number: CLLG783X2201 Start Date*: 2017-11-28
    Sponsor Name:Novartis Pharma AG
    Full Title: A Patient and Investigator-blinded, randomized, placebo controlled study of LLG783 in patients with peripheral artery disease (PAD) and intermittent claudication.
    Medical condition: Peripheral Artery Disease (PAD), Intermittent Claudication
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10022562 Intermittent claudication PT
    20.0 10047065 - Vascular disorders 10034633 Peripheral vascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000687-30 Sponsor Protocol Number: AROAPOC3-2001 Start Date*: 2021-10-04
    Sponsor Name:Arrowhead Pharmaceuticals, Inc.
    Full Title: A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Severe Hypertriglyceridemia
    Medical condition: Severe Hypertriglyceridemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-004645-36 Sponsor Protocol Number: TMP-2501-2019-2 Start Date*: 2021-05-31
    Sponsor Name:Fraunhofer Gesellschaft for its Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP)
    Full Title: Impact of different silymarin dosages to decrease drug-induced elevated liver enzymes compared to placebo in a prospective controlled dose finding Phase IIb trial (SILVER)
    Medical condition: Drug-induced elevated liver enzymes
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10024668 Liver damage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005989-34 Sponsor Protocol Number: 034B20 Start Date*: 2022-08-31
    Sponsor Name:Aphaia Pharma AG
    Full Title: A Phase II, randomized, double-blind, placebo-controlled, parallel-group proof-of-concept study to evaluate efficacy and safety of distal jejunal-release dextrose (Aphaia technology, AT) in obese s...
    Medical condition: Obesity with/without associated endocrine and/or metabolic conditions and/or hypertension and/or NASH and/or NAFL with/without fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004473-32 Sponsor Protocol Number: IDN-6556-14 Start Date*: 2016-12-27
    Sponsor Name:Conatus Pharmaceuticals Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hyperten...
    Medical condition: Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10036200 Portal hypertension PT
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001527-20 Sponsor Protocol Number: 20101155 - TIMI 57 Start Date*: 2011-09-20
    Sponsor Name:Amgen Inc
    Full Title: TIMI 57 - A Double-Blind, Randomized, Placebo-controlled, Multicenter, Dose-ranging Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Combination with HMG-CoA Reductase Inhibitors ...
    Medical condition: Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    13.1 10027433 - Metabolism and nutrition disorders 10020603 Hypercholesterolaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-003373-18 Sponsor Protocol Number: ISIS681257-CS6 Start Date*: 2017-06-28
    Sponsor Name:Akcea Therapeutics, Inc.
    Full Title: A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 681257 Administered Subcutaneously to Patients with Hyperlipoproteinemia(a) and Established Cardiovascular Disease...
    Medical condition: Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020668 Hyperlipoproteinemia LLT
    20.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-005839-28 Sponsor Protocol Number: 0859-019 Start Date*: 2008-09-03
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients ...
    Medical condition: Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004866 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) HU (Completed) FR (Completed) AT (Completed) FI (Completed) NL (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000242-38 Sponsor Protocol Number: BEL114674 Start Date*: 2013-01-09
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: BEL114674: A 2 year study of efficacy and safety of intravenous belimumab versus placebo in subjects with idiopathic membranous nephropathy
    Medical condition: Idiopathic Membranous Nephropathy (IMN)
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004857 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 19 10:16:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA